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Dthis might also be attributed to a lack of physical exertion
and maximum cardiovascular effort to detect differences
in these elderly and frail patients. Objective functional mea-
surements of cardiovascular capacity may have offered
deeper insights. However, 1 PPM-related surgical interven-
tion raises concerns about a potential problem that needs to
be considered when planning a valve-in-valve implantation.
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DrMathewWilliams (New York, NY). This study has a limited
number of patients, so it is hard to make any overwhelming con-
clusions. However, rather than dwell on that, I commend you and
the American Association for Thoracic Surgery for deciding to
address this issue while this technology is in its infancy. I and
several of my colleagues have already changed our surgical strat-
egy in younger patients. We are using tissue valves in much
younger patients with almost a planned bailout strategy in the fu-
ture of performing a transcatheter valve-in-valve rather than
a reoperation.
I have 1 comment about the data. I find it is somewhat difficult
to try to evaluate the data in terms of looking at EOA, AR grades,
andmean gradient as an average for thewhole population when the
reality is that approximately one third had pure aortic stenosis, one
third had pure aortic insufficiency, and one third had mixed. This
leads me to my first question. I realize it is entirely anecdotal, but
can you comment on any clinical differences, functional differ-
ences, in the patients who presented with more aortic stenosis or
more insufficiency? It might make sense that in a patient who
has severe aortic stenosis it would be worth doing this procedure
even if you are going to have some PPM, but perhaps our bar
should be a little higher for those with aortic insufficiency.
Dr Seiffert. As you stressed, the limited number of patients in
the presented study makes it difficult to distinguish any clinical or
functional differences as symptoms or left ventricle dimensions.
What I would draw from our data is that the patients may have
profitedmore from a significant reduction of AR rather than a com-
plete relief of stenosis. Therefore, I would imagine that patients
with AR due to bioprosthetic degeneration would profit the most
from this procedure.
Dr Williams. It would be interesting at some point to see what
their left ventricle dimensions were, but, again, it is a small num-
ber. Can you provide some guidance given that a lot of us are put-
ting tissue valves in younger patients now? Is there an absolute size
that we need to put in patients in whom we are going to try this ap-
proach? Perhaps we need to pick their ideal size and add +1 to that,
even if it means doing a root enlargement more aggressively in
these patients.
Dr Seiffert. We have been discussing this topic thoroughly in
our department. As you already stated, patient age is important
to that matter. If patients receive a bioprosthesis now, and thererdiovascular Surgery c Volume 143, Number 3 623
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Dis a chance they will require a valve replacement because of degen-
eration in 10 or 15 years, we should plan ahead. Because of the po-
tential problem of PPM, we would rather implant a larger
bioprosthesis, even if a root enlargement has to be done to accom-
modate at least a 23-mm valve. Current studies suggest that root
enlargement is not associated with an increase in morbidity and
mortality due to the surgical procedure.
We should still keep in mind, as emphasized by Dr Moon in his
lecture on PPM, that we do not necessarily see a clinical result or
a corollary to the PPM, as determined by echocardiography. Some
of these patients may not reach the level of physical activity nec-
essary to experience symptoms or functional changes (eg, in terms
of left ventricular mass) due to a persistent stenosis in the light of
PPM.
Dr Lucian Lozonschi (Madison, Wis). I congratulate you for an
interesting and timely article. It is inevitable now not to tell pa-
tients, especially for the past year or so, about the option of
valve-in-valve implantation in the future.
I have 2 questions, 1 related to your incidence of paravalvular
leak, which we all think should be zero or very small. I haven’t
seen you report that in the results presented. Were you aware of
any rumors of a smaller valve size that can address that issue, or
for now shall we stick with putting in larger valves (>23)?
Dr Seiffert. I agree that paravalvular regurgitation is not a sig-
nificant problem after valve-in-valve procedures. Apart from 1 pa-
tient with a grade 2 paravalvular regurgitation, the remaining
patients had no or trivial AR. We follow these patients closely
and have not seen any changes in regurgitation or influence on
outcome.
To my knowledge, developments of a cuffed transcatheter
valve-in-valve prosthesis are under way to avoid any paravalvular
leakage. I would imagine this might also reduce the EOA and may
therefore not be beneficial with regard to PPM. I do not have any
information on smaller THVs being developed for implantation
into smaller bioprostheses.
Dr Bansi Koul (Lund, Sweden). Given the small number of pa-
tients, did you have an opportunity to see if these patients who had
the valves preoperatively, and based on the EOA of those valves
already, had some sort of PPM and this is where it became exag-
gerated in the group?624 The Journal of Thoracic and Cardiovascular SurgDr Seiffert. Are you referring to data before valve-in-valve im-
plantation as opposed to afterward?
Dr Koul. Yes. Do you have some data based on the valves they
had in the first instance and from their given BSA that they already
had some degree of PPM that became exaggerated after you did
a valve-in-valve procedure?
Dr Seiffert. The iEOA did not really significantly change after
valve-in-valve implantation. It would have been interesting to ret-
rospectively look at potential PPM immediately after the index
procedure 12.5 years ago, for example, echocardiography mea-
surements from back then. Unfortunately, we do not have these
data. Because EOA calculations based on the geometric EOA pro-
vided by the manufacturer overestimate the actual opening area,
we did not perform these calculations.
Dr Christopher Young (London, UK). We have done more
than 15 valve-in-valve procedures, and we haven’t seen anything
like this in our population. We wouldn’t expect to see gradients
or AR, and yet you showed some deformity when you are actually
putting this device into somebody who has a strong circular annu-
lus. Can you explain why you are seeing problems with regurgita-
tion and the deformity, because I wouldn’t actually expect that?
How bad are the symptoms in these patients who have a mis-
match, how much of it is echocardiographic data, and how much
of it is symptomatic if this procedure is done for symptoms in el-
derly patients?
Dr Seiffert. One patient presented with strong symptoms after
valve-in-valve implantation, NYHA class IV, received reoperative
valve replacement combined with root enlargement, and has been
doing well since then. In the remaining 10 patients, it is difficult to
differentiate the symptoms, because these are elderly patients with
significant comorbidities, such as pulmonary disease. I agree that
a symptom-based approach is appropriate in these elderly patients.
Nevertheless, PPM is a potential problem that has to be considered
when planning valve-in-valve procedures.
In regard to your first question, we agree that paravalvular AR is
not an issue in valve-in-valve procedures. By referring to the
pictures from bench ex vivo valve-in-valve implantations, you cer-
tainly note an uneven stent expansion after implantation of
a 23-mm THV into a 21-mm rigid stent that may result in leaflet
distortion and subsequent transvalvular regurgitation.ery c March 2012
